Preview

Опухоли женской репродуктивной системы

Расширенный поиск

Интенсифицированная неоадъювантная химиотерапия в уплотненном режиме с использованием комбинаций паклитаксела с гемцитабином и доцетаксела с доксорубицином при местно-распространенном раке молочной железы

https://doi.org/10.17650/1994-4098-2012-0-3-4-73-83

Полный текст:

Аннотация

Разработанный режим химиотерапии (ХТ) паклитакселом и гемцитабином с сокращением интервала между циклами до 2 нед позволяет в 1,5 раза сократить сроки проведения предоперационного лечения и может быть изучен далее в неоадъювантной ХТ операбельного рака молочной железы. Интенсифицированная ХТ в режиме паклитаксел 175 мг/м2 1-й день + гемцитабин 2000 мг/м2 1-й день, доцетаксел 70 мг/м2 1-й день + доксорубицин 60 мг/м2 1-й день + колониестимулирующий фактор каждые 2 нед обладает высокой клинической эффективностью и удовлетворительной переносимостью.

Об авторах

И. В. Фрай
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия


В. А. Горбунова
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия


Н. И. Переводчикова
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия


В. П. Летягин
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия


О. А. Анурова
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия


Список литературы

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 году. Вестн РОНЦ 2010;21(1):57−9.

2. Hortobagyi G.N., Buzdar A.U., Strom E.A. et al. Primary chemotherapy for early and advanced breast cancer. Cancer Lett 1995;90(1):103−9.

3. Haagensen C.D., Stout A.P. Carcinoma of the breast. P. I. Results of treatment. Ann Surg 1942;116(6):801−15.

4. Haagensen C.D., Stout A.P. Carcinoma of the breast. P. II. Criteria of operability. Ann Surg 1943;118:859−870,1032−51.

5. Bonadonna G., Valagussa P., Moliterni P. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332(14):901−6.

6. Портной С.М. Лечение местно-распространенного рака молочной железы. Российская научно-практическая конференция «Современные аспекты диагностики и лечения рака молочной железы». Сибирск онкол журн 2008;2:14−22.

7. Coskun U., Gunel N., Onuk E. et al. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer. Neoplasma 2003;50(3):210−6.

8. Jones R.L, Salter J., A'Hern R. et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemo- therapy for breast cancer. Breast Cancer Res Treat 2010;119(2):315−23.

9. Colleoni M., Viale G., Zahrieh D. et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10(19):6662−8.

10. Rouzier R., Perou C.M., Symmans W.F. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;II(16): 5678−85.

11. Carey L.A., Dees E.C., Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329−34.

12. Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and long-term survival in patients with triple- negative breast cancer. J Clin Oncol 2008; 26(8):1275−81.

13. Haagensen C. Diseases of the breast. Philadelphia, Saunders, 1965.

14. Борисов В.И., Сарибекян Э.Л. Нео- адъювантная ХТ рака молочной железы.В кн.: Новое в терапии рака молочной же- лезы. М., 1998. С. 43−7.

15. Тюляндин C.А. Значение предоперационной химиотерапии у больных раком молочной железы. Материалы IV ежегодной Росс онкол конференции, 2009.

16. Colozza M., Gori S., Mosconi A.M. et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol 1996; 19(1):10−7.

17. Smith I.С., Heys S.D., Hutcheon A.W. et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20(6): 1456−66.

18. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005;10(6):370−81.

19. Skipper H.E., Schabel F.M., Wilcox X. Experimental evaluation of potential anticancer agents. XIII: On the criteria and kinetics associated with «curability» of experimental leukemia. Cancer Chemother Rep 1964;35:1−111.

20. Skipper H.E. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28(6):1479−99.

21. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70(1):163−9.

22. Norton L., Simon R., Brereton H.D. et al. Predicting the course of Gompertzian growth. Nature 1976;264(5586):542−55.

23. Hortobagyi G.N., Ames F.C., Buzdar A.U. et al. Management of stage III primary breast cancer with primary chemotherapy surgery, and radiation therapy. Cancer 1988; 62:2507−16.

24. Perloff M., Lesnick G.J., Korzun A. et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B Study. J Clin Oncol 1988;6:261−9.

25. Pierce L.J., Lippman M., Ben-Baruch N. et al. The effect of systemic therapy on local- regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:949−60.

26. Low J.A., Berman A.W., Steinberg S.M. et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067−74.

27. Ueno N.T., Buzdar A.U., Singletary S.E. et al. Combined-modality treatment of inflam- matory breast carcinoma: Twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321−9.

28. Clark J., Rosenman J., Cance W. et al. Extending the indications for breast- conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1998;42:345−50.

29. Kuerer H.M., Newman L.A., Smith T.L. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin- based neoadjuvant chemotherapy. J Clin Oncol 1999;17(2):460−9.

30. Cristofanilli M., Buzdar A.U., Snelge N. et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775−82.

31. Favret A.M., Carlson R.W., Goffinet D.R. et al. Locally advanced breast cancer: Is surgery necessary? Breast J 2001;7:131−7.

32. Heys S.D., Hutcheon A.W., Sarkar T.K. et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3 Suppl 2:S69–74.

33. Harris E.E., Schultz D., Bertsch H. et al. Ten year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1200−18.

34. McIntosh S.A., Ogston K.N., Payne S. et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003;185(6):525−31.

35. Therasse P., Mauriac L., Welnicka-Jaskiewicz M. el al. Final results of a randomized phase III trial comparing cyclo- phosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21(5):843−50.

36. Espinosa E., Morales S., Borrega P. et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol 2004;54(6):546−52.

37. Ezzat A.A., Ibrahim E.M., Ajarim D.S. et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 2004;90(5):968−74.

38. Gajdos C., Tartter P.I., Estabrook A. et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80(1):4−11.

39. Lebowitz P.F., Eng-Wong J., Swain S.M. et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004;10(20):6764−9.

40. De Matteis A., Nuzzo F., D'Aiuto G. et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 2002; 94(4):895−901.

41. Shen J., Valero V., Buchholz Т.А. et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004;11(9):854−60. 42. Thomas E., Holmes F.A., Smith T.L. et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women

42. with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004;22:2294−302.

43. Erol K., Baltali E., Altundag K. et al. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Onkologie 2005;28(2):81−5.

44. Gradishar W.J., Wedam S.B., Jahanzeb M. et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage Ш breast cancer. Ann Oncol 2005;16(8):1297−304.

45. Tham Y.L., Gomez L.F., Mohsin S. et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers, Breast Cancer Res Treat 2005;94(3):279−84.

46. Veyret C., Levy C., Chollet P. et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107(11):2535−44.

47. Ellis G.K., Green S.J., Russell C.A. et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:537−9.

48. Villman K., Ohd J.F., Lidbrink E. et al.A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007;43:1153−60.

49. Von Minckwitz G., Kümmel S., Vogel P. et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100(8):552−62.

50. Manga G.P., Shahi P.K., Urena M.M. et al. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine in locally advanced or inflammatory breast cancer. Breast Cancer 2009, doi: 10.1007/s12282-009-0136-6.


Для цитирования:


Фрай И.В., Горбунова В.А., Переводчикова Н.И., Летягин В.П., Анурова О.А. Интенсифицированная неоадъювантная химиотерапия в уплотненном режиме с использованием комбинаций паклитаксела с гемцитабином и доцетаксела с доксорубицином при местно-распространенном раке молочной железы. Опухоли женской репродуктивной системы. 2012;(3-4):73-83. https://doi.org/10.17650/1994-4098-2012-0-3-4-73-83

For citation:


Frai I.V., Gorbunova V.A., Perevodchikova N.I., Letyagin V.P., Anurova O.A. Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer. Tumors of female reproductive system. 2012;(3-4):73-83. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-3-4-73-83

Просмотров: 179


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)